Aldeyra Therapeutics is a biotechnology company focused on discovering and developing therapies for immune-mediated diseases. The company's approach involves developing pharmaceuticals that modulate reactive aldehyde species (RASP) to treat inflammatory conditions, specifically targeting ocular and systemic ailments. Its product pipeline includes RASP modulators ADX-248 and ADX-246 for systemic and retinal immune-mediated diseases, and late-stage candidates reproxalap for dry eye disease and allergic conjunctivitis, and ADX-2191, a formulation of intravitreal methotrexate for primary vitreoretinal lymphoma and retinitis pigmentosa. Aldeyra has entered into an exclusive option agreement with AbbVie for the development and commercialization of reproxalap in the United States and globally. The company has no approved products for sale and funds its operations through equity and debt financing while advancing clinical trials for its drug candidates.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Biotechnology Homepage aldeyra.com
Sector Healthcare IR page ir.aldeyra.com
Tags
immune-mediated diseases, ophthalmology, dry eye disease, allergic conjunctivitis, vitreoretinal lymphoma, retinitis pigmentosa, rasp modulators, small molecules, clinical stage, inflammation, ADX-248, ADX-246, reproxalap, ADX-2191, AbbVie
Press page —

Metrics

Valuation  
Market cap $ 39.232M
Market cap (USD) $ 39.232M
P/E -2.10
PEG —
P/BV 1.11
P/S —
P/OCF -2.05
P/FCF -1.18
Dividend yield —
Turnover / mcap —
Returns  
ROE -58.7%
ROI -56.9%
ROIC -44.5%
Profit margin —
Growth  
Revenue growing —
Profits growing Yes
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding —
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 27
Quality score -30.8%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Assets 72.059M 104.607M 148.327M 181.292M 233.137M 83.353M 75.518M 95.091M 44.175M 25.188M 28.205M 8.787M 3.743M
Net profit -33.847M -55.851M -37.543M -62.025M -57.776M -37.6M -60.827M -38.893M -22.341M -18.699M -12.09M -5.187M 13.06M
Free cash flow -33.346M -43.209M -30.326M -56.654M -42.564M — -44.994M -30.12M -19.248M -15.159M -9.398M -4.79M —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Share price 5.18 4.99 3.51 6.96 4 6.86 5.81 8.3 6.8 5.35 6.78 7.08 —
Price performance 12m 0.04 0.42 -0.5 0.74 -0.42 0.18 -0.3 0.22 0.27 -0.21 -0.04 — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Borrowings, current (USD) 77,546 116,319 — — — — 911,763 15.1M 31,372 15.2M
Borrowings, non-current (USD) 1.24M 1.22M — 14.5M 11.4M 15.5M 14.9M 0.00 15M 0.00
Lease liabilities (USD) — — — 226,328 233,310 354,839 249,265 510,814 271,631 280,537
Cash and deposits (USD) 12M 20M 47.4M 44.4M 77.9M 230M 144M 143M 54.5M 70M
Right-of-use assets (USD) — — — 201,007 233,310 351,863 249,265 510,814 266,955 275,861
Net debt (borrowings + leases - cash) (USD) -10.7M -18.7M — -29.7M -66.2M -214M -128M -127M -39.2M -54.5M
Cash flow detail
Operating cash flow (USD) -15.1M -19.2M -29.9M -45M -37.5M -42.6M -56.6M -30.3M -43.2M -33.3M
Purchases of property, plant and equipment (USD) -11,810 -24,759 -262,966 -9,529 — -7,806 -16,317 0.00 — —
Change in payables (cash effect) (USD) -575,719 725,522 2.05M -2.85M -426,664 638,064 -886,077 1.2M -1.16M -21,992
Interest paid (cash effect) (USD) -78,128 -91,633 -88,963 -238,491 -1.39M -1.34M -1.34M -1.7M -1.75M -1.69M
Share-based compensation (USD) 2.76M 2.71M 4.14M 8.08M 7.08M 7.11M 8.29M 5.75M 7.97M 6.09M
Free cash flow (OCF - PPE - intangibles) (USD) -15.2M -19.2M -30.1M -45M — -42.6M -56.7M -30.3M — —
Income detail
Research and development expense (USD) 13.2M 16.3M 29.8M 44.4M 24.7M 44.9M 47.3M 29.5M 48.2M 25.7M
↳ 5y CAGR +80.8% +64.3% +26.6% +27.8% +23.7% -0.2% +1.7% +0.8%
Total comprehensive income (USD) -18.7M -22.4M -38.9M -60.8M -37.6M -57.8M -62.1M -37.4M -55.8M -33.9M
Comprehensive income to owners (USD) -18.7M -22.4M -38.9M -60.8M -37.6M -57.8M -62.1M -37.4M -55.8M -33.9M
Reported Mar 30, 2017 Mar 29, 2018 Mar 8, 2019 Mar 12, 2020 Mar 11, 2021 Mar 17, 2022 Mar 9, 2023 Mar 7, 2024 Feb 28, 2025 Feb 27, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On November 17, 2026, Aldeyra Therapeutics, Inc. (the “Company”) received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market (“Nasdaq”) indicating that as result of the closing bid price of the Company’s common stock (“Common Stock”) for the last 30 consecutive business days having been below the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”) the Company was not in compliance with the Minimum Bid Price Requirement (the “Minimum Bid Price Notice”). The Minimum Bid Price Notice has no immediate effect on the continued listing status of the Company’s Common Stock on The Nasdaq Capital Market, and, therefore, the Company’s listing remains fully effective.

Pursuant to Nasdaq Marketplace Rule 5810(c)(3)(A), the Company has been provided an initial compliance period of 180 calendar days, or until May 17, 2027, to regain compliance with the Minimum Bid Price Requirement.

Aldeyra Therapeutics, Inc. — Other Events Bull 0 Bear 6 Clinical/regulatory

Other Events.

On November 9, 2026, Aldeyra Therapeutics, Inc. (“Aldeyra” or the “Company”) announced that the Company has formally requested that the Division of Ophthalmology (the “DO”) of the U.S. Food and Drug Administration (the “FDA”) submit a review jurisdiction request to the FDA’s Office of New Drugs (the “OND”) recommending that review of the Company’s Investigational New Drug application (the “IND”) for ADX-2191 for the treatment of primary vitreoretinal lymphoma (“PVRL”) be transferred to the FDA’s Division of Hematologic Malignancies 2 (“DHM2”). Aldeyra made this request because lymphoma reviews are typically conducted by DHM2, which maintains expertise in local and systemic manifestations of hematogenous cancers. In connection with this request, Aldeyra notified the FDA that it had withdrawn the Special Protocol Assessment (the “SPA”) protocol for ADX-2191 for the treatment of PVRL, which the DO had previously reviewed and agreed to. The submission of the review jurisdiction request is within the DO’s control, and any decision on the request is within the FDA’s discretion.

September 29, 2026

PDF Version

CONCORD, Mass.--(BUSINESS WIRE)--Sep. 29, 2026-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced intent to submit to the U.S. Food and Drug Administration (FDA) a Formal Dispute Resolution Request (FDRR) for reproxalap, an investigational drug candidate, for the treatment of dry eye disease. The FDRR, which is expected to be reviewed by the FDA’s Office of New Drugs (OND), is designed to appeal the March 16, 2026 Complete Response Letter that denied approval of a New Drug Application (NDA) for reproxalap for the treatment of dry eye disease. Submission of the FDRR and a meeting with the OND are expected in the fourth quarter of 2026.

Following an NDA submission and two NDA resubmissions of reproxalap for the treatment of dry eye disease, Aldeyra has received three Complete Response Letters, the first two of which recommended an additional clinical trial to “demonstrate a positive effect on the treatment of ocular symptoms of dry eye” and the most recent of which did not request further clinical trials but stated that the “totality of evidence from the completed clinical trials does not support the effectiveness of the product.” Over the course of the three NDA submissions, Aldeyra has provided data from nine adequate and well-controlled clinical trials, five of which achieved all multiplicity-controlled primary endpoints, consistent with or greater than the success rates of clinical trials conducted for approved dry eye disease products.

The decision to submit the FDRR is based on the outcome of recent Type A and Type D meetings with the FDA Division of Ophthalmology and the Office of Specialty Medicine. Per Prescription Drug User Fee Act target timelines established for the FDRR process, Aldeyra expects to hold a meeting with OND in the fourth quarter of 2026. The timing of the OND FDRR decision will depend on a number of factors, including whether the deciding official requests additional information or determines there is a need to discuss the FDRR with internal or external experts or convene an advisory panel, the occurrence and timing of which are uncertain.

“We remain steadfast in our commitment to working with the FDA to provide a novel therapeutic approach for the treatment of dry eye disease, a condition often regarded by patients and physicians as inadequately addressed by available therapies,” stated Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer of Aldeyra Therapeutics. “Based on the activity of reproxalap across a number of clinical trial designs, and against a backdrop of FDA dry eye disease product approvals that have applied considerable discretion, we are optimistic in the outcome of the FDRR.”

Additionally, based on reported cash and cash equivalents of $45.1M as of June 30, 2026, Aldeyra updated financial guidance to include extension of operational cash runway into 2029.

Conference Call & Webcast Information

Aldeyra will host a conference call at 8:00 a.m. ET today to discuss the FDRR. The dial-in numbers are (833) 461-5787 for domestic callers and (585) 542-9983 for international callers. The access code is 720 219 137. A live webcast of the conference call will be available on the Investor Relations page of the company’s website at https://ir.aldeyra.com. After the live webcast, the event will remain archived on the Aldeyra Therapeutics website for 90 days.

About Aldeyra

Aldeyra Therapeutics is a biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated diseases. Our approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Our product candidates include RASP (reactive aldehyde species) modulators ADX-248 and chemically related molecules for the potential treatment of systemic and retinal immune-mediated diseases. Our late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of primary vitreoretinal lymphoma.

Safe Harbor Statement

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding Aldeyra’s future expectations, plans, and prospects, including without limitation statements regarding: the goals, opportunity, and potential for reproxalap; the outcome and expected timing of discussions with the FDA; the timing and outcome of the expected FDRR submission; and projected operational cash runway. Aldeyra intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terms such as, but not limited to, “may,” “might,” “will,” “objective,” “intend,” “should,” "could," “can,” “would,” “expect,” “believe,” “anticipate,” “project,” “on track,” “scheduled,” “target,” “design,” “estimate,” “predict,” “contemplates,” “likely,” “potential,” “continue,” “ongoing,” “aim,” “plan,” or the negative of these terms, and similar expressions intended to identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions, and uncertainties. Aldeyra is at an early stage of development and may not ever have any products that generate significant revenue. All of Aldeyra's development timelines may be subject to adjustment depending on recruitment rate, regulatory review, preclinical and clinical results, funding, and other factors that could delay the initiation, enrollment, or completion of clinical trials. Important factors that could cause actual results to differ materially from those reflected in Aldeyra's forward-looking statements include, among others, the timing of enrollment, commencement and completion of Aldeyra's clinical trials, the timing and success of preclinical studies and clinical trials conducted by Aldeyra and its development partners; delay in or failure to obtain regulatory approval of Aldeyra's product candidates, including as a result of the FDA not accepting Aldeyra’s regulatory filings, issuing a complete response letter, or requiring additional clinical trials or data prior to review or approval of such filings or in connection with resubmissions of such filings; the ability to maintain regulatory approval of Aldeyra's product candidates, and the labeling for any approved products; the risk that prior results, such as signals of safety, activity, or durability of effect, observed from preclinical or clinical trials, will not be replicated or will not continue in ongoing or future studies or clinical trials involving Aldeyra's product candidates in clinical trials focused on the same or different indications; updated or refined data based on Aldeyra's continuing or post-hoc review and quality control analysis of clinical data; the scope, progress, expansion, and costs of developing and commercializing Aldeyra's product candidates; uncertainty as to Aldeyra’s ability to commercialize (alone or with others) and obtain reimbursement for Aldeyra's product candidates following regulatory approval, if any; the size and growth of the potential markets and pricing for Aldeyra's product candidates and the ability to serve those markets; Aldeyra's expectations regarding Aldeyra's expenses and future revenue, the timing of future revenue, the sufficiency or use of Aldeyra's cash resources and needs for additional financing; the rate and degree of market acceptance of any of Aldeyra's product candidates; Aldeyra's expectations regarding competition; Aldeyra's anticipated growth strategies; Aldeyra's ability to attract or retain key personnel; Aldeyra’s commercialization, marketing and manufacturing capabilities and strategy; Aldeyra's ability to establish and maintain development partnerships; Aldeyra’s ability to successfully integrate acquisitions into its business; Aldeyra's expectations regarding federal, state, and foreign regulatory requirements; political, economic, legal, social, and health risks, public health measures, and war or other military actions, that may affect Aldeyra’s business or the global economy; regulatory developments in the United States and foreign countries; Aldeyra's ability to obtain and maintain intellectual property protection for its product candidates; the anticipated trends and challenges in Aldeyra's business and the market in which it operates; and other factors that are described in the “Risk Factors” and “Management's Discussion and Analysis of Financial Condition and Results of Operations” sections of Aldeyra's Annual Report on Form 10-K for the year ended December 31, 2025 and Aldeyra’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, which are on file with the Securities and Exchange Commission (SEC) and available on the SEC's website at https://www.sec.gov/. Additional factors may be described in those sections of Aldeyra’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, expected to be filed with the SEC in the fourth quarter of 2026, and Aldeyra’s other filings with the SEC.

In addition to the risks described above and in Aldeyra's other filings with the SEC, other unknown or unpredictable factors also could affect Aldeyra's results. No forward-looking statements can be guaranteed and actual results may differ materially from such statements. The information in this release is provided only as of the date of this release, and Aldeyra undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260929404066/en/

**Investor & Media Contact:**David Burke (917) 618-2651 [email protected]

Source: Aldeyra Therapeutics, Inc.

Safe Harbor Disclosure

This video content contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding Aldeyra’s possible or assumed future results of operations, expenses and financing needs, business strategies and plans, research and development plans or expectations, trends, the structure, timing and success of Aldeyra’s planned or pending clinical trials, expected milestones, market sizing, pricing and reimbursement, competitive position, regulatory matters, industry environment and potential growth opportunities, among other things. Actual results or trends could differ materially from those contemplated by these forward-looking statements. For more information, please refer to the risk factors discussed in Aldeyra's periodic filings with the SEC, including the most recent Form 10-Q or 10-K. Any forward-looking statements that are made in the video content are based on assumptions as of the original date of the creation of such video, and Aldeyra undertakes no obligation to update these statements as a result of new information or future events.

Continue to video

Prompts

Aldeyra Therapeutics, Inc. (ticker ALDX), listed in United States.

Company History

Date Change Detail
Jan 2, 2014 Renamed Aldexa Therapeutics, Inc. → ALDEYRA THERAPEUTICS, INC.

ETFs Holding Aldeyra Therapeutics, Inc.

ETF Weight in ETF Shares Market value As of
DFAS 0.00% 132 $ 83.17 Nov 12, 2026